An extensive study focusing on obesity and chronic kidney disease uncovers the beneficial effects of sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery. Obesity, known to drive chronic kidney disease, can cause kidney disease independently of diabetes, hypertension, and cardiovascular disease. Diabetes and obesity together accelerate chronic kidney disease. Recent randomized controlled trials...